Extraglycemic effects of glp-1-based therapeutics: addressing metabolic and cardiovascular risks associated with type 2 diabetes.

[1]  J. Oyama,et al.  glucagon-like peptide 1 analog liraglutide reduces TNF-- induced oxidative tress and inflammation in endothelial cells , 2012 .

[2]  N. Al-Daghri,et al.  GLP-1 analogue, Liraglutide protects human umbilical vein endothelial cells against high glucose induced endoplasmic reticulum stress , 2012, Regulatory Peptides.

[3]  L. Ding,et al.  Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells , 2011, Acta Pharmacologica Sinica.

[4]  K. Lee,et al.  Neuroprotective effect of the glucagon‐like peptide‐1 receptor agonist, synthetic exendin‐4, in streptozotocin‐induced diabetic rats , 2011, British journal of pharmacology.

[5]  N. Calcutt,et al.  GLP‐1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice , 2011, Diabetes, obesity & metabolism.

[6]  S. Yamagishi,et al.  Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level. , 2011, Metabolism: clinical and experimental.

[7]  K. Yoo,et al.  Ischemia‐induced changes in glucagon‐like peptide‐1 receptor and neuroprotective effect of its agonist, exendin‐4, in experimental transient cerebral ischemia , 2011, Journal of neuroscience research.

[8]  D. Dutka,et al.  Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease , 2011, Heart.

[9]  N. Hattori,et al.  Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[10]  R. Cuddihy,et al.  One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial , 2011, International journal of clinical practice.

[11]  A. Dear,et al.  A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model , 2011, Diabetes & vascular disease research.

[12]  B. Bode,et al.  Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes , 2011, Diabetes, obesity & metabolism.

[13]  R. Testa,et al.  The Possible Protective Role of Glucagon-Like Peptide 1 on Endothelium During the Meal and Evidence for an “Endothelial Resistance” to Glucagon-Like Peptide 1 in Diabetes , 2011, Diabetes Care.

[14]  M. Trautmann,et al.  DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. , 2011, The Journal of clinical endocrinology and metabolism.

[15]  W. L. Jin,et al.  Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury. , 2011, Biochemical and biophysical research communications.

[16]  S. Miyamoto,et al.  Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes , 2011, Diabetologia.

[17]  A. Miyazaki,et al.  Abstract 10278: Incretin-Based Treatments Prevent the Development of Atherosclerotic Lesions in Apolipoprotein E-Null Mice , 2010 .

[18]  P. Reaven,et al.  Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. , 2010, Atherosclerosis.

[19]  M. Taskinen,et al.  One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. , 2010, Atherosclerosis.

[20]  Å. Sjöholm,et al.  Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor , 2010, Molecular and Cellular Endocrinology.

[21]  R. Bergenstal,et al.  Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial , 2010, The Lancet.

[22]  H. Satoh,et al.  RETRACTED ARTICLE: A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells , 2010, Diabetologia.

[23]  J. Northrup,et al.  Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial , 2010, The Lancet.

[24]  M. Mattson,et al.  Enhancing the GLP‐1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells , 2010, Journal of neurochemistry.

[25]  R. Berria,et al.  Weight Loss, Glycemic Control, and Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort Database , 2010, Diabetes Care.

[26]  Lewis J Smith,et al.  Lung function in young adults predicts airflow obstruction 20 years later. , 2010, The American journal of medicine.

[27]  M. S. Lewis,et al.  Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. , 2010, The American journal of medicine.

[28]  M. Taskinen,et al.  Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition , 2010, Diabetes Care.

[29]  R. Cuddihy,et al.  Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial , 2010, The Lancet.

[30]  J. Rosenstock,et al.  Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents , 2010, Diabetes Care.

[31]  P. Reaven,et al.  Improvement of Postprandial Endothelial Function After a Single Dose of Exenatide in Individuals With Impaired Glucose Tolerance and Recent-Onset Type 2 Diabetes , 2010, Diabetes Care.

[32]  S. N. Murthy,et al.  The synthetic GLP-I receptor agonist, exenatide, reduces intimal hyperplasia in insulin resistant rats , 2010, Diabetes & vascular disease research.

[33]  B. Zinman,et al.  Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD) (Diabetes Care (2009) 32, (1224-1230)) , 2010 .

[34]  A. D'Angelo,et al.  Exenatide versus glibenclamide in patients with diabetes. , 2010, Diabetes technology & therapeutics.

[35]  B. Hoogwerf,et al.  Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study , 2010, Cardiovascular diabetology.

[36]  M. S. Lewis,et al.  Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin , 2010, Diabetes Care.

[37]  S. Yamagishi,et al.  Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. , 2010, Biochemical and biophysical research communications.

[38]  R. Kawamori,et al.  Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4 , 2010, Diabetes.

[39]  J. Holst,et al.  Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? , 2010, Diabetologia.

[40]  D. Drucker,et al.  The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice , 2010, Diabetologia.

[41]  S. Jones,et al.  Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study , 2009 .

[42]  A. Vaag,et al.  Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial , 2009, Diabetologia.

[43]  P. Hellström.  GLP-1: Broadening the incretin concept to involve gut motility , 2009, Regulatory Peptides.

[44]  K. Laugero,et al.  Exenatide improves hypertension in a rat model of the metabolic syndrome. , 2009, Metabolic syndrome and related disorders.

[45]  M. Maeng,et al.  Lack of cardioprotection from subcutaneously and preischemic administered Liraglutide in a closed chest porcine ischemia reperfusion model , 2009, BMC cardiovascular disorders.

[46]  J. Rosenstock,et al.  Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) , 2009, The Lancet.

[47]  Diana L. Williams,et al.  Minireview: finding the sweet spot: peripheral versus central glucagon-like peptide 1 action in feeding and glucose homeostasis. , 2009, Endocrinology.

[48]  B. Göke,et al.  GLP‐1 regulates gastroduodenal motility involving cholinergic pathways , 2009, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[49]  A. Dear,et al.  A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. , 2009, The Journal of endocrinology.

[50]  B. Zinman,et al.  Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD) , 2009, Diabetes Care.

[51]  S. Colagiuri,et al.  Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[52]  A. Nishiyama,et al.  Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. , 2009, Biochemical and biophysical research communications.

[53]  P. Doevendans,et al.  Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. , 2009, Journal of the American College of Cardiology.

[54]  B. Bode,et al.  Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial , 2009, The Lancet.

[55]  C. Deacon.  Potential of liraglutide in the treatment of patients with type 2 diabetes , 2009, Vascular health and risk management.

[56]  Yu-Ting Kuo,et al.  Differential patterns of neuronal activation in the brainstem and hypothalamus following peripheral injection of GLP-1, oxyntomodulin and lithium chloride in mice detected by manganese-enhanced magnetic resonance imaging (MEMRI) , 2009, NeuroImage.

[57]  R. Henkelman,et al.  GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice , 2009, Diabetes.

[58]  D. Matthews,et al.  Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes , 2008, Diabetes Care.

[59]  A. Dear,et al.  Glucagon-like peptide-1 attenuates tumour necrosis factor-alpha-mediated induction of plasminogen [corrected] activator inhibitor-1 expression. , 2010, The Journal of endocrinology.

[60]  D. Drucker,et al.  Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study , 2008, The Lancet.

[61]  D. Drucker,et al.  Brain Glucagon-Like Peptide-1 Regulates Arterial Blood Flow, Heart Rate, and Insulin Sensitivity , 2008, Diabetes.

[62]  R. DeFronzo,et al.  Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study , 2008, Current medical research and opinion.

[63]  T. Nyström,et al.  The Potential Beneficial Role of Glucagon-like Peptide-1 in Endothelial Dysfunction and Heart Failure Associated with Insulin Resistance , 2008, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[64]  T. Vilsbøll,et al.  Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes , 2008, Diabetic medicine : a journal of the British Diabetic Association.

[65]  L. Macconell,et al.  Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. , 2008, Clinical therapeutics.

[66]  D. Drucker,et al.  Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways , 2008, Circulation.

[67]  D. Klonoff,et al.  Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. , 2008, Current medical research and opinion.

[68]  L. B. Knudsen,et al.  Liraglutide, a Once‐daily Human Glucagon‐like Peptide‐1 Analog, Minimizes Food Intake in Severely Obese Minipigs , 2007, Obesity.

[69]  D. Drucker,et al.  Biology of incretins: GLP-1 and GIP. , 2007, Gastroenterology.

[70]  L. B. Knudsen,et al.  Liraglutide, a Long-Acting Glucagon-Like Peptide-1 Analog, Reduces Body Weight and Food Intake in Obese Candy-Fed Rats, Whereas a Dipeptidyl Peptidase-IV Inhibitor, Vildagliptin, Does Not , 2007, Diabetes.

[71]  D. Klonoff,et al.  Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. , 2007, Clinical therapeutics.

[72]  R. Wexler,et al.  Initiation of therapy for patients with essential hypertension or comorbid conditions. , 2006, Primary care.

[73]  D. Drucker,et al.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.

[74]  M. Mocanu,et al.  Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. , 2005, Diabetes.

[75]  J. Holst,et al.  Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. , 2004, American journal of physiology. Endocrinology and metabolism.

[76]  J. Holst,et al.  Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. , 2004, American journal of physiology. Endocrinology and metabolism.

[77]  A. Huber,et al.  Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. , 2004, The Journal of clinical endocrinology and metabolism.

[78]  R. Schwartz,et al.  Diet-induced weight loss is associated with an improvement in beta-cell function in older men. , 2004, The Journal of clinical endocrinology and metabolism.

[79]  R. Shannon,et al.  Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion , 2004, Circulation.

[80]  T. Kigoshi,et al.  Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells , 2004, Autonomic Neuroscience.

[81]  R. Roman,et al.  Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats , 2003, Journal of hypertension.

[82]  M. Mattson,et al.  Protection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4 , 2002, Journal of Pharmacology and Experimental Therapeutics.

[83]  C. Saper,et al.  Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. , 2002, The Journal of clinical investigation.

[84]  J. Holst,et al.  Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study , 2002, The Lancet.

[85]  B. Göke,et al.  Effects of glucagon-like peptide-1(7–36)amide on motility and sensation of the proximal stomach in humans , 2002, Gut.

[86]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[87]  J. Holst,et al.  GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. , 1999, The American journal of physiology.

[88]  L. Simons,et al.  Beneficial Effect on Average Lipid Levels From Energy Restriction and Fat Loss in Obese Individuals With or Without Type 2 Diabetes , 1998, Diabetes Care.

[89]  A. Astrup,et al.  Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. , 1998, The Journal of clinical investigation.

[90]  J. Habener,et al.  Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. , 1996, Endocrinology.

[91]  S. Mojsov,et al.  Distribution of GLP-1 and PACAP receptors in human tissues. , 1996, Acta physiologica Scandinavica.